Computational modeling of substitution effect on HIV-1 non-nucleoside reverse transcriptase inhibitors with Kier- Hall electrotopological state (E-state) indices

Internet Electronic Journal of Molecular Design

Volumn 11, Issue 1, 2012, Pages 55-67

  Sapre, Nitin S ^a   Pancholi, Nilanjana ^a   Gupta, Swagata ^a  

^a SHRI G S INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

Author keywords

Kier Hall electrotopological state indices; Multiple linear regression; Non nucleoside reverse transcriptase inhibitors; QSAR; Quantitative structure activity relationships

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84860898488     PISSN: None     EISSN: 15386414     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. W. A. Haseltine, Molecular biology of the human immunodeficiency virus type 1, FASEB J. 1991, 5, 2349-2360.
2. A. S. Fauci, The human immunodeficiency virus: infectivity and mechanisms of pathogenesis, Science, 1988, 239, 617-622.
3. W. Blattner, R. C. Gallo, H. M. Temin, HIV causes AIDS, Science, 1988, 241, 515-516.
4. O. Bagasra, S. P. Hauptman, H. W. Lischner, M. Sachs, R. J. Pomerantz, Detection of human immunodeficiency virus type 1 provirus in mononuclear cells by in situ polymerase chain reaction, N. Engl. J. Med. 1992, 326, 1385-1391.
5. A. S. Fauci, Immunopathogenic mechanisms in human immunodeficiency virus (HIV) infection, Ann. Intern. Med. 1991, 114, 678-693.
6. P. A. Volberding, S. W. Lagakos, M. A. Koch, et al., Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimetre, N. Engl. J. Med. 1990, 322, 941-949.
7. M. V. Ragni, L. A. Kingsley, S. J. Zhou, The effect of antiviral therapy on the natural history of human immunodeficiency virus infection in a cohort of hemophiliacs, J. Acquir. Immune. Defic. Syndr. 1992, 5, 120-126.
8. N. M. H Graham, S. L Zeger, L. P. Park, et al., Effect of zidovudine and Pneumocystis carinii pneumonia prophylaxis on progression of HIV-1 infection to AIDS, Lancet 1991, 338, 265-269.
9. G. F Lemp, S. F Payne, D. Neal, T. Temelso, G. W. Rutherford, Survival trends for patients with AIDS, JAMA, 1990, 263, 402-406.
10. B. Tindall, D. A. Cooper, Primary HIV infection: host responses and intervention strategies, AIDS 1991, 5, 1-14.
11. E. De Clercq, What can be expected from non-nucleoside reverse transcriptase inhibitors in the treatment of human immunodeficiency virus type 1 infection? Rev. Med. Virol. 1996, 97-117.
12. E. De Clercq, Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection, Farmaco 1999, 54, 26-45.
13. G. Campiani, A. Ramunno, G. Maga, V. Nacci, C. Fattorusso, B. Catalanotti, B. Morelli, E. Novellino, Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: past, present, and future perspectives, Curr. Pharm. Des. 2002, 8, 615-657.
14. M. Baba, H. Tanakas, E. De Clercq, R. Pauwels, J. Balzarini, D. Schols, H. Nakashima, C. F. Perno, R. T. Walker, T. Miyasaka, Highly specific inhibition of human immunodeficiency virus type-1 by a novel 6-substituted acyclouridine derivative, Biochem Biophys. Res. Commun. 1989, 165, 1375-1381.
15. C. F. Venezia, K. J. Howard, M. E. Ignatov, L. A. Holladay, M. D. Barkley, Effects of Efavirenz Binding on the Subunit Equilibria of HIV-1 Reverse Transcriptase, Biochemistry 2006, 45, 2779-2789.
16. R. Pauwels, K. Andries, Z. Debyser, P. Van Daele, D. Schols, A. M. Vandamme, C. G. M. Janssen, J. Anne, G. Cauwenbergh, J. Desmyter, J. Heykants, M. A. C. Janssen, E. De Clercq, P. A. J. Janssen, Potent and Highly Selective Human Immunodeficiency Virus Type 1 (HIV-1) Inhibition by a Series of-Anilinophenylacetamide derivatives targeted at HIV-1 Reverse Transcriptase, Proc. Natl. Acad. Sci. USA 1993, 90, 1711-1715.
17. J. Balzarini, M. J. Pérez-Pérez, A. San-Felix, D. C. F. Schols, Perno, A. Vandamme, M. J. Camarasa, E. De Clercq, 2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5''-(4''-amino-1'',2"-oxathiole-2'',2'-dioxide) pyrimidine (TSAO) nucleoside analogues: highly selective inhibitors of human immunodeficiency virus type 1 that targeted at the viral reverse transcriptase, Proc. Natl. Acad. Sci. USA 1992, 89, 4392-4396.
18. D. L. Romero, M. Busso, C. K. Tan, F. Reusser, J. R. Palmer, S. M. Poppe, P. F. Aristoff, K. M. Downey, A. G. So, L. Resnick; W. G. Tarpley, Nonnucleoside Reverse Transcriptase Inhibitors that Potently and Specifically Block Human Immunodeficiency Virus Type 1 replication, Proc. Natl. Acad. Sci. USA 1991, 88, 8806-8810.
19. V.J. Merluzzi, K.D. Hargrave, M. Labadia, K. Grozinger, M. Skoog, J.C. Wu, C.K. Shih, K. Eckner, S. Hattox, J. Adams, Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor, Science, 1990, 250, 1411-1413.
20. R. Pauwels, K. Andries, J. Desmyter, D. Schols, M. J. Kukla, H. J. Breslin, A. Raeymaeckers, J. Van Gelder, R. Woestenborghs, J. Heykants, Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivative, Nature, 1990, 343, 470-474.
21. C. Ahgren, K. Backro, F. W. Bell, A. S. Cantrell, M. Clemens, J. M. Colacino, J. B. Deeter, J. A. Engelhardt, M. Hogberg, S. R. Jaskunas, N. G. Johanssons, The PETT series, a new class of potent non-nucleoside inhibitors of human immunodeficiency virus type-1 reverse transcriptase, Antimicrob. Agents Chemother. 1995, 39, 1329-1335.
22. To date six nucleosides have been approved by the FDA: AZT, 3TC, d4T, ddI, ddC, and abacavir.
23. P. P. Mager, A check on rational drug design: Molecular simulation of the allosteric inhibition of HIV-1 reverse transcriptase, Med. Res. Rev. 1997, 17, 235-276.
24. E. Arnold, K. Das, J. Ding, P.N. Yadav, Y. Hsiou, P.L. Boyer, S. H. Hughes, Targeting HIV reverse transcriptase for anti-AIDS drug design: structural and biological considerations for chemotherapeutic strategies, Drug. Des. Discov. 1996, 13, 29-47.
25. H. Jonckheere, J. Anne, E. De Clercq, The HIV-1 reverse transcription (RT) process as target for RT inhibitors, Med. Res. Rev. 2000, 20, 129-154.
26. D. Richman, C. K. Shih, I. Lowy, J. Rose, P. Prodanovich, S. Goff, and Griffin, Human Immunodeficiency Virus Type 1 Mutants Resistant to Nonnucleoside Inhibitors of Reverse Transcriptase arises in Tissue Culture, Proc. Natl. Acad. Sci. USA 1991, 88, 11241-11245.
27. H. Chan. Joseph, 2-Amino-6-arylsulfonylbenzonitriles as Non-nucleoside Reverse Transcriptase Inhibitors of HIV-1, J. Med. Chem. 2001, 44, 1866-1882.
28. Kier-Hall, E-calc version 1.1, 1999.
29. M. Randic, P. G. Seybold, Molecular Shape as a Critical Factor in Structure-Property-Activity Studies, SAR QSAR Environ. Res. 1993, 1, 77-85.
30. M. Randić, In Search of Structural Invariants, J. Math. Chem. 1992, 9, 97-146.
31. N. Trinajstić, Chemical Graph Theory; CRC Press: Boca Raton, FL, 1983, Vols. 1 and 2.
32. P. G. Seybold, M. May, U. A. Bagal, Molecular Structure-Property Relationships, J. Chem. Educ. 1987, 64, 575-581.
33. L. B. Kier, L. H. Hall, Molecular Structure Description: The Electrotopological State, Academic Press, San Diego, 1999.
34. L. B. Kier, L. H. Hall, Design of molecules from quantitative structure-activity relationship models. III. Role of higher order path counts: Path Three, J. Chem. Inf. Comput. Sci. 1993, 33, 598-603.
35. L. B. Kier, L. H. Hall, B. K. Mohney, The electro-topological state: An atom index for QSAR, Quant. Struct.-Act. Relat. 1991, 10, 43-51.
36. B. Testa, L. B. Kier, The concept of structure in structure-activity relations by studies and drug design, Med. Res. Rev, 1991, 11, 35-48.
37. L. B. Kier, L. H. Hall, The generation of molecular structures for a graph based equations, Quant. Struct.-Act. Relat. 1994, 12, 383-388.
38. L. B. Kier, L. H. Hall, Quantitative information analysis: The new center of gravity in medicinal chemistry, Med. Chem. Res. 1997, 7,335-339.
39. L. B. Kier, L. H. Hall, J. W. Frazer, Design of molecules from quantitative structure-activity relationship models. I. Information transfer between path and vertex degree counts, J. Chem. Inf. Comput. Sci. 1993, 33, 143-147.
40. C. Hansch, A quantitative approach to biochemical structure-activity relationships, Acc. Chem. Res. 1969, 2, 232-239.
41. Sagata Regression ver. 1.0, Sagata Regression ver. 1.0, http://www.sagata.com.
42. WinIDAMS 1.2, http://www.unesco.org/idams, July 2004.